Drugs / heat-labile enterotoxin of E. coli (LT)
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01067781 | Feb → Sep 2010 | diarrheal disease | Intercell USA, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00751777 | Sep 2008 → Nov 2009 | — | Intercell USA, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00565461 | Nov 2007 → Jul 2008 | — | Intercell USA, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00672035 | Oct → Dec 2006 | acute diarrhea | Intercell USA, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Heat-Labile Enterotoxin of E. coli (LT) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01067781 ↗ |
| Modality | Vaccine | “LT Vaccine Patch” NCT00565461 ↗ |
| Route | Topical | “37.5ug patch applied on either the deltoid or the thigh” NCT00565461 ↗ |